Abstract
Hypertension is a common, early feature of polycystic kidney disease (PKD) that contributes to the development of cardiovascular disease, a leading cause of mortality in these patients. Effective control of hypertension is therefore essential. Clinical trials show that renal denervation (RDN) can reduce blood pressure in hypertensive patients with chronic kidney disease, however, the impact of RDN on PKD patients as a specific cohort has not been examined. RDN involves surgical destruction of both the sympathetic and sensory components of the renal nerve, but which is responsible for any clinically relevant effects is not clear.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
